Abstract
The advent of tyrosine kinase inhibitors (TKI) has improved prognosis and outcome
of patients with chronic myelogenous leukemia (CML) considerably. In comparison to
imatinib, first line use of second generation inhibitors nilotinib, dasatinib and
bosutinib lead to faster and deeper molecular remissions accompanied by a novel adverse
event profile. Essential part of the management of CML patients is a consequent use
of cytogenetic and molecular follow up with standardized methods to regularly assess
the remission status. Long lasting remission without treatment in an important minority
of patients prompted the hope for curability of CML. The use of interferon alpha in
parallel with or after TKI therapy is associated with the induction of an immune response
against the leukemic clone with further improved remission rate. The cooperative management
of CML patients permits the early use of novel treatment options in patients at risk.
Vom fachlichen Standpunkt aus gesehen, stellt die chronische myeloische Leukämie (CML)
eine Modellerkrankung für Diagnostik und Therapie neoplastischer Erkrankungen dar.
Die zugrundeliegende zytogenetische Aberration, das Philadelphia-Chromosom mit der
Genfusion sowie der mehrstufige Verlauf ermöglichen es, molekular-zytogenetische Erkenntnisse
auf die klinische Anwendung zu übertragen. Dabei spielen nicht nur „Meilensteine“
eine Rolle.
Schlüsselwörter
Chronische myeloische Leukämie - Tyrosinkinase-Inhibitoren - BCR-ABL
Key words
chronic myelogenous leukemia - tyrosine kinase inhibitors - BCR-ABL
